Sunday, May 19, 2024
logo
Update At 14:00    USD/EUR 0,92  ↑+0.0002        USD/JPY 151,69  ↑+0.174        USD/KRW 1.347,35  ↑+6.1        EUR/JPY 164,16  ↑+0.143        Crude Oil 85,49  ↓-0.76        Asia Dow 3.838,83  ↑+1.8        TSE 1.833,50  ↑+4.5        Japan: Nikkei 225 40.846,59  ↑+448.56        S. Korea: KOSPI 2.756,23  ↓-0.86        China: Shanghai Composite 3.015,74  ↓-15.745        Hong Kong: Hang Seng 16.512,92  ↓-105.4        Singapore: Straits Times 3,27  ↑+0.018        DJIA 22,58  ↓-0.23        Nasdaq Composite 16.315,70  ↓-68.769        S&P 500 5.203,58  ↓-14.61        Russell 2000 2.070,16  ↓-4.0003        Stoxx Euro 50 5.064,18  ↑+19.99        Stoxx Europe 600 511,09  ↑+1.23        Germany: DAX 18.384,35  ↑+123.04        UK: FTSE 100 7.930,96  ↑+13.39        Spain: IBEX 35 10.991,50  ↑+39.3        France: CAC 40 8.184,75  ↑+33.15        

Company Database


KM BIOLOGICS CO., LTD.

about this company

Address:

1-6-1 Okubo, Kita-ku, Kumamoto, 860-8568, Japan

Phone Number:

+81-96-344-2755

Fax Number:

+81-96-300-3395

Company Contact Email:

global-strategy@kmbiologics.com

Website:

https://www.kmbiologics.com/en/

Employees:

2,029 (June 2023)

Capital:

USD 71.4M [Total USD 7.6B for the Meiji group companies] (1USD=140JPY)

Revenue:

USD 306M [Total USD 7.6B for the Meiji group companies] (1USD=140JPY)

Main Clients:

Meiji Seika Pharma

Introduction of your company & business:

KM Biologics supplies first-rate biological products and services with sophisticated skills and knowledge based on over 70 years of combined experience. Our main businesses include the following:

Human Vaccines

Blood Plasma Products

Veterinary Vaccines

Newborn Screening

Mission/Vision:

Our responsibility as disease prevention and treatment professionals is to continuously push the limits of life sciences to shape a healthy future for people around the world.

History:

1945: Establishment of our predecessor, Kaketsuken

1946: Vaccine production for smallpox and cholera, a combined vaccine against typhus and paratyphoid, and a tetanus antitoxin started.

1964: Approval of DPT vaccine.

1988: Launch of Bimmugen – the first Japanese recombinant Hepatitis B vaccine.

1991: Launch of Bolheal – the first Japanese fibrin sealant

2001: Succeeded in full-length cDNA cloning of ADAMTS13

2014: Launch of a new haemostatic treatment for haemophillia patients with inhibitors: Byclot – human coagulation factor VIIa containing factor X

2018: Kaketsuken joined Meiji Group and renamed to KM Biologics.

2023: Approval of Quintovac, a pentavalent vaccine for use in Japan.

Key Products or Services:

Seasonal and pandemic influenza vaccines, Pentavalent vaccine, Japanese encephalitis vaccine, Human coagulation factors, Newborn Screening

Factory Equipment:

Dedicated facilities and equipment for manufacturing various types of vaccines and plasma derived therapies regularly inspected and approved by the Japanese authorities (PMDA).

Technology / R&D activities:

With a commitment to discovery, innovation, and excellence, our scientists carry out cutting-edge research that helps contribute to a healthy future for people around the world.

Inactivated COVID-19 vaccine

Live attenuated tetravalent dengue vaccine

Hexavalent vaccine

Recombinant vaccines

International Operations:

So far KM Biologics has supplied vaccines only in Japan. We are looking for strategic partners to explore the overseas markets.

Business Achievements:

After the 2009 pandemic influenza outbreak, we were the first in the world to establish a domestic vaccine supply system – and today we boast the capability to supply the vaccine to around 57 million people

Awards:

KM Biologics has been included in the list of “Certified Health & Productivity Management Outstanding Organizations Recognition Program” by the Ministry of Economy, Trade and Industry three consecutive years, as a company that has an excellent health and productivity management system in place.

Company Goals & Objectives:

Overseas expansion of registered products and testing systems.

Further broadening of our product portfolio with a focus on immunologic, hematologic and congenital disease area.

Becoming a strategic development, manufacturing and sales partner mainly in Japan and APAC region.

Developing new generation of pharmaceuticals by adoption of new modalities